Just As I Said It Would — UK Single-Payer Now Covers Pembrolizumab For Lung — After Sharper Pencil Price Negotiations

I won’t unduly belabor the point, but this is increasingly the new multi-national model for new drug pricing (Keytruda® pricing being a rather pointed example): often rather steep discounts from US list prices.

Even as to truly revolutionary treatments, the world’s governmental-affiliated payers will increasingly seek — and win — price concessions from big pharma. And Mr. Frazier is (smartly, I think, given the incoming Administration is also likely to target drug pricing) talking peace, on price increases, more generally.

Here is the overnight item — you may read it for yourself. But it was all easily predictable, back from June to October 2016. So, to quote the old adage: “We’ve established what they are — now we are simply haggling over. . . price.” [But it used to refer primarily to investment bankers.] That was uncalled for. Now stricken.




There are no comments on this post.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: